Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
SLNO

SLNO - Soleno Therapeutics Inc Stock Price, Fair Value and News

42.35USD-2.67 (-5.93%)Market Closed

Market Summary

SLNO
USD42.35-2.67
Market Closed
-5.93%

SLNO Stock Price

View Fullscreen

SLNO RSI Chart

SLNO Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-27.2

Price/Sales (Trailing)

1.1K

EV/EBITDA

-156.67

Price/Free Cashflow

-46.09

SLNO Price/Sales (Trailing)

SLNO Profitability

Operating Margin

26.92%

EBT Margin

-816.18%

Return on Equity

-36.29%

Return on Assets

-30.82%

Free Cashflow Yield

-2.17%

SLNO Fundamentals

SLNO Revenue

Revenue (TTM)

1.5M

SLNO Earnings

Earnings (TTM)

-52.0M

Earnings Growth (Yr)

-156.08%

Earnings Growth (Qtr)

-89.43%

Breaking Down SLNO Revenue

Last 7 days

-7.0%

Last 30 days

-6.3%

Last 90 days

-2.5%

Trailing 12 Months

747%

How does SLNO drawdown profile look like?

SLNO Financial Health

Current Ratio

11.23

SLNO Investor Care

Shares Dilution (1Y)

309.01%

Diluted EPS (TTM)

-2.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20170000
2016812.6K1.0M1.2M1.5M
20152.3M1.7M1.0M387.6K
20130003.0M

Tracking the Latest Insider Buys and Sells of Soleno Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 06, 2024
mario ernest
acquired
-
-
6,500
-
Jun 06, 2024
pauls matthew
acquired
-
-
6,500
-
Jun 06, 2024
sinclair andrew
acquired
-
-
6,500
-
Jun 06, 2024
volck birgitte
acquired
-
-
6,500
-
Jun 06, 2024
harris william g
acquired
-
-
6,500
-
May 21, 2024
mario ernest
acquired
279,000
4.5
62,000
-
Apr 30, 2024
vivo opportunity, llc
sold
-15,851,600
45.13
-351,242
-
Apr 29, 2024
vivo opportunity, llc
sold
-35,850,000
47.8
-750,000
-
Apr 01, 2024
yen kristen
sold
-91,693
41.3407
-2,218
see remarks
Apr 01, 2024
mackaness james h
sold
-213,937
41.3406
-5,175
chief financial officer

1–10 of 50

Which funds bought or sold SLNO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
reduced
-83.2
-5,462,360
1,187,700
-%
May 17, 2024
Ikarian Capital, LLC
reduced
-4.21
442,310
24,199,600
2.65%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
33.8
175,249
589,784
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-67.36
-1,194,540
635,066
-%
May 16, 2024
AWM Investment Company, Inc.
sold off
-100
-805,000
-
-%
May 15, 2024
JANUS HENDERSON GROUP PLC
added
13.75
21,093,000
122,698,000
0.07%
May 15, 2024
STATE STREET CORP
added
93.57
21,359,000
41,540,400
-%
May 15, 2024
Tudor Investment Corp Et Al
new
-
693,103
693,103
-%
May 15, 2024
WELLINGTON MANAGEMENT GROUP LLP
added
66.26
6,571,590
15,129,000
-%
May 15, 2024
MORGAN STANLEY
added
105
2,411,180
4,451,330
-%

1–10 of 44

Are Funds Buying or Selling SLNO?

Are funds buying SLNO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SLNO
No. of Funds

Unveiling Soleno Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 01, 2024
vivo opportunity fund holdings, l.p.
22.5%
7,316,851
SC 13D/A
Feb 14, 2024
commodore capital lp
2.3%
7e+05
SC 13G/A
Feb 14, 2024
nantahala capital management, llc
9.9%
3,068,031
SC 13G/A
Feb 13, 2024
janus henderson group plc
8.3%
2,523,897
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
5.99%
1,826,814
SC 13G/A
Oct 23, 2023
perceptive advisors llc
10.1%
3,074,542
SC 13D/A
Oct 16, 2023
carlyle group inc.
9.99%
2,893,615
SC 13D/A
Oct 12, 2023
commodore capital lp
6.0%
885,741
SC 13G
Oct 12, 2023
adage capital partners gp, l.l.c.
8.69%
1,327,000
SC 13G
Oct 11, 2023
vivo opportunity fund holdings, l.p.
30.5%
8,418,093
SC 13D/A

Recent SEC filings of Soleno Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 06, 2024
8-K
Current Report
May 23, 2024
4
Insider Trading
May 10, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
May 07, 2024
8-K
Current Report

Peers (Alternatives to Soleno Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Soleno Therapeutics Inc News

Latest updates
MarketBeat12 Jun 202408:32 pm
The Motley Fool29 Apr 202407:00 am

Soleno Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2017Q32017Q22017Q12016Q42016Q32016Q22016Q12015Q42015Q32015Q22015Q12013Q42013Q3
Revenue-97.0%4,000134,500265,000283,788329,000388,000447,00021,555247,00097,000---
Cost Of Revenue-100.0%-42,000209,000410,306399,00051,000461,000256,68356,00022,00018,000--
Gross Profit100.0%--41,00056,00067,982-70,000-49,000-14,000-15,211191,00075,0004,000--
Interest Expenses---------1,000--1,000-571,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-6.6%16918164.0031.0020.0026.0032.0037.0043.0036.0043.0049.0057.0065.0072.0079.0032.0038.0029.0034.0039.00
  Current Assets-11.8%15117154.0020.009.0016.0021.0025.0030.0022.0029.0035.0043.0050.0056.0063.0016.0021.0012.0017.0021.00
    Cash Equivalents-74.8%43.0017052.0019.008.0015.0020.0024.0029.0021.0028.0034.0042.0049.0056.0062.0015.0021.0011.0016.0019.00
  Net PPE125.0%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities9.8%25.0023.0040.0019.0017.0016.0017.0017.0016.0018.0022.0021.0019.0019.0024.0023.0023.0023.0014.0020.0015.00
  Current Liabilities17.0%13.0012.0029.009.008.007.007.007.007.008.009.008.0010.009.008.008.007.005.003.003.002.00
Shareholder's Equity-9.0%14315823.0012.003.0010.0015.0020.0026.0018.0020.0027.0038.0046.0048.0056.009.0015.0015.0014.0024.00
  Retained Earnings-7.7%-297-276-265-254-245-237-231-225-219-213-210-202-191-182-179-171-163-157-143-144-134
  Additional Paid-In Capital1.7%441434288267248248247246245231231230229228228227173173158158158
Accumulated Depreciation-100.0%-0.00---0.00---0.00---0.00---0.00---
Shares Outstanding5.2%33.0032.0015.009.009.008.009.007.005.005.005.005.00---------
Float----33.00---8.00---61.00---98.00---28.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-98.9%-12,528-6,300-6,306-5,566-6,728-5,143-4,656-4,620-6,362-6,863-5,406-8,013-7,488-6,867-6,164-6,534-5,659-5,076-4,719-3,893-3,687
  Share Based Compensation237.6%6,4451,9092,2011,2046316326835716444189068571,095393374341392204153220248
Cashflow From Investing-Infinity%-115,244-----6.00----13.00-5.00--4.00-4.00---103441-6.00-10.00
Cashflow From Financing-99.2%938123,55839,40117,060--342-28214,032-5.00-2.00-125-42.00-19553,963-4.00----
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SLNO Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses  
Research and development$ 14,602$ 5,316
General and administrative8,4722,854
Change in fair value of contingent consideration401299
Total operating expenses23,4758,469
Operating loss(23,475)(8,469)
Other income, net  
Interest income, net2,077113
Total other income, net2,077113
Net loss(21,398)(8,356)
Other comprehensive income (loss)  
Net unrealized loss on marketable securities(105)0
Foreign currency translation adjustment(1)16
Total comprehensive loss$ (21,504)$ (8,340)
Net loss per common share basic$ (0.59)$ (0.88)
Net loss per common share diluted$ (0.59)$ (0.88)
Weighted-average common shares outstanding used to calculate basic net loss per common share36,208,3719,447,350
Weighted-average common shares outstanding used to calculate diluted net loss per common share36,208,3719,447,350

SLNO Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 42,847$ 169,681
Short-term investments106,780 
Prepaid expenses and other current assets1,5961,677
Total current assets151,223171,358
Long-term assets  
Property and equipment, net2712
Operating lease right-of-use assets338407
Intangible assets, net8,2638,749
Long-term investments8,821 
Other long-term assets165165
Total assets168,837180,691
Current liabilities  
Accounts payable8,0223,149
Accrued compensation1,2263,135
Accrued clinical trial site costs2,3953,393
Operating lease liabilities310273
Other current liabilities1,5111,555
Total current liabilities13,46411,505
Long-term liabilities  
Contingent liability for Essentialis purchase price11,95011,549
Long-term lease liabilities37130
Total liabilities25,45123,184
Commitments and contingencies (Note 6)
Stockholders’ equity  
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 33,337,079 and 31,678,159 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively3332
Additional paid-in-capital441,267433,885
Accumulated other comprehensive loss(106)
Accumulated deficit(297,808)(276,410)
Total stockholders’ equity143,386157,507
Total liabilities and stockholders’ equity$ 168,837$ 180,691
SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
 CEO
 WEBSITEhttps://soleno.life
 INDUSTRYBiotechnology
 EMPLOYEES25

Soleno Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Soleno Therapeutics Inc? What does SLNO stand for in stocks?

SLNO is the stock ticker symbol of Soleno Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Soleno Therapeutics Inc (SLNO)?

As of Fri Jun 14 2024, market cap of Soleno Therapeutics Inc is 1.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLNO stock?

You can check SLNO's fair value in chart for subscribers.

What is the fair value of SLNO stock?

You can check SLNO's fair value in chart for subscribers. The fair value of Soleno Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Soleno Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SLNO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Soleno Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SLNO is over valued or under valued. Whether Soleno Therapeutics Inc is cheap or expensive depends on the assumptions which impact Soleno Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLNO.

What is Soleno Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, SLNO's PE ratio (Price to Earnings) is -27.2 and Price to Sales (PS) ratio is 1.1 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLNO PE ratio will change depending on the future growth rate expectations of investors.